Recent developments in the management of postmenopausal osteoporosis with bisphosphonates: enhanced efficacy by enhanced compliance

被引：39

作者：

Boonen, S. ^{[1
,2
,3
]}

Vanderschueren, D. ^{[1
,2
]}

Venken, K. ^{[1
]}

Milisen, K. ^{[3
]}

Delforge, M. ^{[4
]}

Haentjens, P. ^{[5
]}

机构：

[1] Katholieke Univ Leuven, Dept Expt Med, Louvain, Belgium

[2] Katholieke Univ Leuven, Ctr Metab Bone Dis, Louvain, Belgium

[3] Katholieke Univ Leuven, Div Geriatr Med, Louvain, Belgium

[4] Katholieke Univ Leuven, Dept Oncol, Louvain, Belgium

[5] Vrije Univ Brussel, Ctr Outcomes Res, Brussels, Belgium

来源：

JOURNAL OF INTERNAL MEDICINE | 2008年 / 264卷 / 04期

关键词：

bisphosphonate; compliance; ibandronate; intravenous; postmenopausal osteoporosis; zoledronic acid;

D O I：

10.1111/j.1365-2796.2008.02010.x

中图分类号：

R5 [内科学];

学科分类号：

1002 [临床医学]; 100201 [内科学];

摘要：

Bisphosphonates are the current mainstay of treatment for postmenopausal osteoporosis. Although daily oral dosing is effective, it is associated with poor compliance, partly because of the pre and postdose fasting and posture requirements. This negatively impacts treatment outcomes, leading to a reduced clinical benefit. Improved, yet still suboptimal adherence has been noticed with less frequent bisphosphonate dosing e.g. once-weekly and once-monthly oral regimens. The recently approved quarterly intravenous (i.v.) injection regimen of ibandronate and yearly i.v. infusion of zoledronic acid are attractive options in the management of postmenopausal osteoporosis. These regimens may assure quarterly and year long compliance.

引用

页码：315 / 332

页数：18

共 93 条

[1]

[Anonymous], 2003, Adherence to Long-Term Therapies: Evidence for action

[2]

Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors [J].

Badros, A ;

Weikel, D ;

Salama, A ;

Goloubeva, O ;

Schneider, A ;

Rapoport, A ;

Fenton, R ;

Gahres, N ;

Sausville, E ;

Ord, R ;

Meiller, T .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (06) :945-952

[3]

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors [J].

Bamias, A ;

Kastritis, E ;

Bamia, C ;

Moulopoulos, LA ;

Melakopoulos, L ;

Bozas, G ;

Koutsoukou, V ;

Gika, D ;

Anagnostopoulos, A ;

Papadimitriou, C ;

Terpos, E ;

Dimopoulos, MA .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (34) :8580-8587

[4]

Bartl R, 2005, ANN RHEUM DIS, V64, P364

[5]

BARTL R, 2007, BISPHOSPHONATES MED, P52

[6]

BARTL R, 2007, BISPHOSPHONATES MED, P20

[7]

Bisphosphonates in the treatment of osteoporosis [J].

Bell, NH ;

Johnson, RH .

ENDOCRINE, 1997, 6 (02) :203-206

[8]

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis [J].

Black, Dennis M. ;

Delmas, Pierre D. ;

Eastell, Richard ;

Reid, Ian R. ;

Boonen, Steven ;

Cauley, Jane A. ;

Cosman, Felicia ;

Lakatos, Peter ;

Leung, Ping Chung ;

Man, Zulema ;

Mautalen, Carlos ;

Mesenbrink, Peter ;

Hu, Huilin ;

Caminis, John ;

Tong, Karen ;

Rosario-Jansen, Theresa ;

Krasnow, Joel ;

Hue, Trisha F. ;

Sellmeyer, Deborah ;

Eriksen, Erik Fink ;

Cummings, Steven R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (18) :1809-1822

[9]

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures [J].

Black, DM ;

Cummings, SR ;

Karpf, DB ;

Cauley, JA ;

Thompson, DE ;

Nevitt, MC ;

Bauer, DC ;

Genant, HK ;

Haskell, WL ;

Marcus, R ;

Ott, SM ;

Torner, JC ;

Quandt, SA ;

Reiss, TF ;

Ensrud, KE .

LANCET, 1996, 348 (9041) :1535-1541

[10]

Weekly administration of alendronate: Rationale and plan for clinical assessment [J].

Bone, HG ;

Adami, S ;

Rizzoli, R ;

Favus, M ;

Ross, PD ;

Santora, A ;

Prahalada, S ;

Daifotis, A ;

Orloff, J ;

Yates, J .

CLINICAL THERAPEUTICS, 2000, 22 (01) :15-28

← 1 2 3 4 5 6 7 8 9 10 →